Whereas circulating adiponectin is reduced in the sera of patients with type 2 diabetes (T2D) and in patients with cardiovascular disease (CVD) [1], systemic adiponectin is elevated in type 1 diabetes mellitus (T1D), that is also associated with macro- and microvasculature complications [11,12]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.